ADC Outsourcing Market Tops $2B as US Capacity Surges

US-based manufacturers dominate a sector reshaped by 780 active trials and accelerating reshoring investment

2 Apr 2026

The global market for contract manufacturing of antibody-drug conjugates has exceeded $2bn, with analysts projecting it will reach $3.21bn by 2035, according to an industry report published on 1 April 2026. The figures reflect a structural shift in how biopharma companies approach one of their most technically demanding production challenges.

ADCs combine a targeted antibody with a toxic cancer-killing payload via a chemical linker, a process requiring specialist containment facilities and multi-step conjugation expertise. Few drug developers maintain this capability in-house, making outsourcing to contract development and manufacturing organisations the dominant model across the sector.

Demand shows little sign of easing. Over 780 active ADC clinical trials are generating near-continuous need for manufacturing capacity, supported by a pipeline of 614 clinical candidates and 28 approved therapies.

North America has emerged as the sector's manufacturing base. Approximately 85% of ADC contract manufacturers globally are US-based, with reshoring pressure accelerating domestic capacity expansion. Veranova, based in Massachusetts, is among companies that have committed to expanding bioconjugation infrastructure. The broader biopharma contract manufacturing market is forecast to grow from $22.40bn in 2025 to $34.15bn by 2030.

Around 60% of outsourcing partnerships in the ADC space have been formed within the past three years, a pace that reflects how rapidly supply chains are being reconfigured.

R&D spending on ADC platforms rose 38% year-on-year in 2024, and commercial production demand has grown alongside a succession of regulatory approvals. Contract manufacturers are positioning themselves as central to the next phase of oncology drug development.

Whether current capacity commitments will prove sufficient, or whether bottlenecks emerge as the clinical pipeline matures into commercial-scale demand, remains an open question.